Development of a blood test for EGFR testing in lung cancer
Research type
Research Study
Full title
Point of Care blood device for fast and reliable prediction of drug response in non small cell lung carcinoma patients from blood samples (LungCard)
IRAS ID
131385
Contact name
Michael J Lind
Contact email
Sponsor organisation
Hull and East Yorkshire NHS trust
Research summary
10% of patients with non small cell lung cancer harbour a mutation in the epidermal growth factor receptor. These patients are better treated with drugs called receptor tyrosine kinase inhibitors than with conventional chemotherapy. To test for this mutation a piece of the tumour is required. These tests are routinely performed on all NSCLC patients. Often this is not possible because the patient is too ill or too small a piece of tumour for these tests to be performed. Therefore a point of use of blood would be preferable.
REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
13/NE/0242
Date of REC Opinion
14 Aug 2013
REC opinion
Further Information Favourable Opinion